PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer
Open Access
- 15 August 2023
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (8) , e0290031
Abstract
The long non-coding RNA (LncRNA) PAXIP1 antisense RNA 1 (PAXIP1-AS1) was found to promote proliferation, migration, EMT, and apoptosis of ovarian cancer (OC) cells in OC cell lines, but the relationship between PAXIP1-AS1 expression and clinical characteristics, prognosis, and immune infiltration of OC patients and its regulatory network are unclear. 379 OC tissues were collected from The Cancer Genome Atlas (TCGA) database. 427 OC tissues and 88 normal ovarian tissues were collected from GTEx combined TCGA database. 130 OC samples were collected from GSE138866. Kruskal-Wallis test, Wilcoxon sign-rank test, logistic regression, Kaplan-Meier method, Cox regression analysis, Gene set enrichment analysis (GSEA), and immuno-infiltration analysis were used to evaluate the relationship between clinical characteristics and PAXIP1-AS1 expression, prognostic factors, and determine the significant involvement of PAXIP1-AS1 in function. QRT-PCR was used to validate the expression of PAXIP1-AS1 in OC cell lines. Low PAXIP1-AS1 expression in OC was associated with age (P = 0.045), histological grade (P = 0.011), and lymphatic invasion (P = 0.004). Low PAXIP1-AS1 expression predicted a poorer overall survival (OS) (HR: 0.71; 95% CI: 0.55–0.92; P = 0.009), progression free interval (PFS) (HR: 1.776; 95% CI: 1.067–2.955; P = 0.001) and disease specific survival (DSS) (HR: 0.67; 95% CI: 0.51–0.89; P = 0.006). PAXIP1-AS1 expression (HR: 0.711; 95% CI: 0.542–0.934; P = 0.014) was independently correlated with PFS in OC patients. GSEA demonstrated that neutrophil degranulation, signaling by Interleukins, GPCR-ligand binding, G alpha I signaling events, VEGFAVEGFR-2 signaling pathway, naba secreted factors, Class A 1 Rhodopsin-Like Receptors, PI3K-Akt signaling pathway, and Focal Adhesion-PI3K-Akt-mTOR-signaling pathway were differentially enriched in PAXIP1-AS1 high expression phenotype. PAXIP1-AS1 was significantly downregulated in OC cell lines compared with IOSE29 cell line. The expression of PAXIP1-AS1 was associated with immune infiltration. low expression of PAXIP1-AS1 was correlated with poor OS (HR: 0.52; 95% CI: 0.34–0.80; P = 0.003) from GSE138866. There were some genomic variations between the PAXIP1-AS1 high and low expression groups. Low expression of PAXIP1-AS1 was significantly associated with poor survival and immune infiltration in OC. PAXIP1-AS1 could be a promising prognosis biomarker and response to immunotherapy for OC.Keywords
Funding Information
- Xuzhou Key R&D Programme (ZYSB20210489)
This publication has 36 references indexed in Scilit:
- The emerging role of lncRNAs in cancerNature Medicine, 2015
- Long noncoding RNAs: Novel insights into gastric cancerCancer Letters, 2015
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2Genome Biology, 2014
- Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human CancerImmunity, 2013
- GSVA: gene set variation analysis for microarray and RNA-Seq dataBMC Bioinformatics, 2013
- The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expressionGenome Research, 2012
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- The Emergence of lncRNAs in Cancer BiologyCancer Discovery, 2011
- Long Noncoding RNAs with Enhancer-like Function in Human CellsCell, 2010
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005